Duaij Saif

Duaij Saif

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2025 in Indian Journal of Anaesthesia
Verified
Journal Article
Open access
Abdullah M AlharranAbdullah M Alharran
Abdullah M Alharran
MAMuteb N. Alotaibi
Muteb N. Alotaibi
YAYaqoub Y. Alenezi
Yaqoub Y. Alenezi
YAYousef M. Alharran
Yousef M. Alharran
AAAHMAD ALAHMAD
AHMAD ALAHMAD
AAAhmad Y. Almohammad
Ahmad Y. Almohammad
Background and Aims: Brachial plexus block (BPB) is advantageous for elective orthopaedic or reconstructive upper limb surgery. However, the optimal local anaesthetic in BPB remains debatable. Therefore, we aim to investigate the efficacy and safety of levobupivacaine versus ropivacaine in BPB for upper limb surgery. Methods: A systematic review and meta-analysis synthesising randomised controlled trials (RCTs), retrieved by systematically searching PubMed, EMBASE, WOS, SCOPUS, Google Scholar, and CENTRAL since inception till June 2024. Continuous and dichotomous outcome variables were pooled using mean difference (MD) and risk ratio (RR), with a 95% confidence interval (CI), using Stata v. 17. We assessed heterogeneity using the Chi-square test and I2 statistic. Results: Sixteen RCTs and 939 patients were included. Levobupivacaine was significantly associated with a longer sensory block duration [MD: 1.66 (95% CI: 1.43, 1.89), P < 0.001] and motor block duration [MD: 1.18 (95% CI: 0.11, 2.26), P = 0.03]. However, there was no difference between both groups in time to sensory block [MD: −0.30 (95% CI: −1.31, 0.71), P = 0.56], time to motor block [MD: −0.29 (95% CI: −1.26, 0.67), P = 0.55], pain score [MD: −0.48 (95% CI: −2.13, 1.16), P = 0.56], rescue analgesia rate [RR: 0.94 (95% CI: 0.74, 1.20), P = 0.64], and complications [RR: 0.47 (95% CI: 0.20, 1.13), P = 0.09]. Conclusions: Levobupivacaine is significantly associated with a longer duration of sensory and motor block in patients undergoing BPB for upper limb surgery compared to ropivacaine, with a similar safety profile. However, there was no difference regarding the time to onset of the sensory or motor block.

1 January 2026 in Medicina
Verified
Journal Article
Open access
PDF file
Abdullah M AlharranAbdullah M Alharran
Abdullah M Alharran
WAWaleed Bader Alazemi
Waleed Bader Alazemi
SASaad A Alajmi
Saad A Alajmi
YBYousiff A Bahman
Yousiff A Bahman
OAOsamah Alhajri
Osamah Alhajri
DSDuaij Saif
Duaij Saif
Background and Objectives: Effective pain control after laparoscopic colorectal surgery is crucial for Enhanced Recovery After Surgery (ERAS) protocols. The transversus abdominis plane block (TAPB) provides somatic analgesia but lacks visceral coverage. The quadratus lumborum block (QLB) has emerged as an alternative, potentially offering both somatic and visceral blockade, but its superiority is debated. This systematic review and meta-analysis aimed to compare the analgesic efficacy of QLB versus TAPB in this setting. Materials and Methods: A comprehensive search of PubMed, Scopus, CENTRAL, and Web of Science was conducted for randomized controlled trials (RCTs) up to November 2025. Primary outcomes were 24 h postoperative and intraoperative opioid consumption. Secondary outcomes included pain scores, length of hospital stay (LoS), surgery duration, and adverse events. Standardized mean differences (SMD) and risk ratios (RR) were pooled. Results: Five RCTs involving 520 patients were included. No significant difference was found in 24 h postoperative opioid consumption (SMD: −1.62, 95% CI [−3.45, 0.20]; p = 0.08) or intraoperative opioid consumption (SMD: 0.38, 95% CI [−0.36, 1.12]; p = 0.31). QLB provided better, transient pain relief at rest at 12 h (SMD: −0.30, 95% CI [−0.52, −0.07]; p = 0.01) and during movement at 6 h (SMD: −0.20, 95% CI [−0.49, −0.09]; p = 0.01). No other time points for pain showed significant differences. QLB was associated with a shorter surgery duration (MD: −5.61 min, 95% CI [−10.38, −0.85]; p = 0.02), but not LoS (p = 0.53) or rates of PONV (p = 0.24) or dizziness (p = 0.32). Conclusions: With uncertain evidence, QLB and TAPB showed no significant difference in opioid consumption. QLB demonstrated a statistically significant but transient early analgesic advantage. This heterogeneity may be due to different QLB techniques, warranting further investigation.

31 October 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
AHAdla Bakri Hassan
Adla Bakri Hassan
RHRowida Mohamed Elamin Ibrahim Hamid
Rowida Mohamed Elamin Ibrahim Hamid
SASaja H. Alamien
Saja H. Alamien
NKNamaa A. Khalil
Namaa A. Khalil
DSDuaij Saif
Duaij Saif
Haitham JahramiHaitham Jahrami
Haitham Jahrami
Background: Methotrexate (MTX) is the most used anti-rheumatic drug for the treatment of early rheumatoid arthritis (ERA) patients, with an adequate response rate of only 30–40%. Thus, early detection of response failure is very crucial to prevent permanent disability. Objectives: We aimed to provide an update on the current evidence of potential predictive biomarkers of MTX treatment response (MTX-TR) in patients with ERA. Materials and Methods: PubMed/MEDLINE, Scopus, EBSCO, and Cochrane Library were searched for studies that investigated a multitude of predictive metabolites of MTX-TR in ERA patients during the 2000–2024 period. This study was registered in PROSPERO (ID: CRD42024547651). Results: We determined that 31 out of 102 metabolites studied were the best predictive of MTX-TR in ERA, using clinical response (DAS28-ESR score). Our results on serum protein profiles revealed that higher pre-treatment levels of myeloid-related proteins, MTX–polyglutamates, choline, inosine, hypoxanthine, guanosine, nicotinamide, and diglyceride, and lower pre-treatment levels of N-methyl isoleucine, 2,3-dihydroxy butanoic acid, nor-nicotine, glucosylceramide, and itaconic acid, were associated with a good MTX-TR. However, lower baseline plasma itaconate and its derivatives and haptoglobin, but a higher baseline level of galactosylated glycans (FA2G) of IgG1, were associated with a good response to MTX. The results on immune cell biology indicated that higher pre-treatment of regulatory B cells, lower pre-treatment of Treg, and RDW were correlated with a good MTX-TR. The results on inflammatory biomarkers showed that a lower IL-1ra/IL1B ratio and IL-6 levels after MTX indicated a good response. Conclusions: This study provides an update on the current evidence of the potential predictive metabolites for the best MTX-TR in ERA patients. We revealed that few biomarkers resulted in a remission state of patients with ERA. These biomarkers are promising but not yet ready for routine clinical use; they warrant validation in larger prospective trials. We recommend that, for the implementation of personalized medicine, these biomarkers should be the first-line biomarkers for use in routine clinical practice after validation.

AHAdla Bakri Hassan
Adla Bakri Hassan
MMMeenas B. Mohamed
Meenas B. Mohamed
MMMeerage B. Mohamed
Meerage B. Mohamed
DSDuaij Saif
Duaij Saif
IAIbrahim Alqahtani
Ibrahim Alqahtani
Amgad El-Baz EL-AGROUDYAmgad El-Baz EL-AGROUDY
Amgad El-Baz EL-AGROUDY
Rheumatoid arthritis (RA) and osteoarthritis (OA) both impair health-related quality of life (HRQoL), but the two have not been compared in Bahrain. This cross-sectional study assessed HRQoL in patients with RA, with OA, and with both conditions together (RA + OA) at two Bahraini tertiary hospitals, using the validated Ferrans and Powers Quality of Life Index. Independent-samples t-tests and Mann–Whitney U tests compared RA with OA, one-way analysis of variance (ANOVA) and Kruskal–Wallis tests compared subgroups, and multiple linear regression identified predictors. Ninety-two patients with RA and 98 with OA participated, 17 of whom had RA + OA. Total HRQoL was comparable between RA and OA (75.4 ± 10.9 versus 76.2 ± 11.2; p = 0.606) and correlated most strongly with the health and functioning subscale (RA: ρ = 0.885; OA: ρ = 0.939). Significant differences (p < 0.05 before FDR) emerged within specific subgroups, RA patients scoring lower, most notably at ages 71 years and above. Patients with RA + OA reported significantly lower HRQoL than either single disease across multiple domains (p < 0.05 before FDR). The optimal model explained 30.3% of the variance. Predictors of quality of life (QoL) beyond diagnostic label were functional limitation, socioeconomic factors and medication use, supporting stratified, patient-centered care for high-risk subgroups and for patients with overlapping rheumatic disease.